RHHBY Roche Holding AG Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
05:01
Jun 02
Jun 02
FDA accepts Roche's new drug application for giredestrant in ER-positive early-stage breast cancer following positive Phase III results.
11:08
Apr 23
Apr 23
Roche breast cancer drug is blockbuster.
Roche's new breast cancer drug (Giredestrant or similar) has blockbuster potential because it targets hormone receptor positive breast cancer (70% of patients), reduces risk of death/recurrence by over 30%, is well-tolerated, and is the first new hormone treatment in over 20 years. The market overreacted to trial data, and the drug will be one of Roche's biggest medicines.
HIGH
21:53
Mar 19
Mar 19
The author correctly predicted the failure of Roche's MANATEE study, highlighting a potential shift in the competitive landscape for myostatin drugs.
HIGH
10:50
Mar 06
Mar 06
Roche's experimental obesity shot "disappointed investors" with weight loss comparable to a placebo. The obesity market is a duopoly (Novo/Lilly). Roche failing to clear the bar removes a potential competitor but severely damages Roche's growth narrative in this high-value sector. SHORT/AVOID Roche as it falls behind in the GLP-1 race. Roche's legacy portfolio outperforms or they acquire a new biotech asset.
About RHHBY Analyst Coverage
Buzzberg tracks RHHBY (Roche Holding AG) across 3 sources. 1 bullish vs 1 bearish calls from 4 analysts. Sentiment: evenly split. 4 total trade ideas tracked.